Reaction
Peripheral T-Cell Lymphoma Unspecified reporting signals
As of the last recalculation, Peripheral T-Cell Lymphoma Unspecified appears in 579 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is BRENTUXIMAB VEDOTIN (PRR 383.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Brentuximab Vedotin | 92 | 383.4 | 386.9 |
| Bendamustine Hcl | 19 | 45.5 | 45.6 |
| Bleomycin Sulfate | 12 | 42.6 | 42.7 |
| Doxorubicin | 80 | 37.3 | 37.3 |
| Axicabtagene Ciloleucel | 10 | 37.0 | 37.1 |
| Everolimus Tablets | 13 | 28.5 | 28.5 |
| Doxorubicin Hydrochloride | 23 | 26.3 | 26.3 |
| Cyclophosphamide Injection, Solution | 102 | 24.9 | 24.9 |
| Cyclophosphamide | 102 | 24.9 | 24.9 |
| Cyclophosphamide For Injection | 102 | 24.9 | 24.9 |
| Etoposide | 46 | 24.3 | 24.4 |
| Ifosfamide | 12 | 20.5 | 20.5 |
| Fludarabine Phosphate | 20 | 18.9 | 18.9 |
| Gemcitabine | 19 | 17.9 | 17.9 |
| Gemcitabine Hydrochloride | 21 | 14.7 | 14.7 |